George Yancopoulos - Aug 13, 2021 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
President and Chief Scientific, Director
Signature
/s/**George D. Yancopoulos
Stock symbol
REGN
Transactions as of
Aug 13, 2021
Transactions value $
-$31,264,263
Form type
4
Date filed
8/17/2021, 04:13 PM
Previous filing
Aug 6, 2021
Next filing
Dec 23, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Sale -$483K -773 -0.08% $625.00 937K Aug 13, 2021 Direct F1
transaction REGN Common Stock Sale -$29.3M -46.9K -5.01% $625.25 890K Aug 16, 2021 Direct F1, F2
transaction REGN Common Stock Sale -$1.44M -2.3K -0.26% $626.10 887K Aug 16, 2021 Direct F1, F3
holding REGN Common Stock 5.85K Aug 13, 2021 By 401(k) Plan
holding REGN Common Stock 214K Aug 13, 2021 By Trust for Chldn. F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 Represents volume-weighted average price of sales of 46,925 shares of Company stock on August 16, 2021 at prices ranging from $625.00 to $625.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price.
F3 Represents volume-weighted average price of sales of 2,302 shares of Company stock on August 16, 2021 at prices ranging from $626.00 to $626.14. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price.
F4 As investment trustee of trusts for the benefit of the reporting person's children.